Vitamin B6 (Pyridoxine / Pyridoxal-5'-Phosphate) for Nausea and Vomiting

Finding: In women with severe baseline nausea (pre-treatment score >7), pyridoxine produced a significantly greater fall in nausea VAS than placebo (mean fall 4.3 vs 1.8; p<0.01). Vomiting episodes were also significantly reduced in the pyridoxine arm (8/31 still vomiting after treatment vs 15/28 placebo; p<0.05). No benefit was seen in women with mild baseline nausea. First modern RCT establishing B6 efficacy and the basis for ACOG first-line recommendation.

Finding: Pyridoxine produced a significantly greater decrease in mean nausea score than placebo (2.9 ± 2.2 vs 2.0 ± 2.7; p=0.0008) and significantly fewer vomiting episodes after day 2. Effect was strongest in women with severe nausea (baseline score >6). At a low dose of only 30 mg/day, B6 was effective for mild-to-moderate NVP, broadening the dose range supported by RCT evidence and underpinning later ACOG/SOGC first-line recommendations.

Finding: Low-to-moderate quality evidence supports pyridoxine (B6) as effective for reducing nausea compared with placebo (effect estimated from Sahakian 1991, Vutyavanich 1995 and others); pyridoxine plus doxylamine showed clearer benefit on PUQE/nausea scores with no increase in adverse pregnancy outcomes. The review concludes that B6 (alone or combined with doxylamine) is supported as a first-line pharmacological option, while noting heterogeneity in outcome measures and limited head-to-head data. This SR forms the evidence base for ACOG PB-189 first-line guidance.

Finding: Across pooled evidence, pyridoxine alone (10-75 mg/day) and doxylamine-pyridoxine combination significantly reduced nausea and vomiting versus placebo in early pregnancy without increased adverse fetal outcomes. Combined formulation showed the most consistent benefit and is the only FDA-approved option for NVP. The review reinforces B6 as the first-step pharmacotherapy after lifestyle/dietary measures, aligned with ACOG PB-189 and SOGC algorithms.

Finding: ACOG PB-189 designates pyridoxine monotherapy or pyridoxine-doxylamine combination as first-line pharmacological treatment for NVP after non-pharmacological measures fail (Level A evidence). The guideline cites Sahakian 1991, Vutyavanich 1995, Matthews/Cochrane 2015 and the doxylamine-pyridoxine RCTs as supporting evidence. Reaffirmed in subsequent ACOG bulletin cycles; remains the dominant guideline for NVP management in North America.